Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Calliditas Therapeutics - Stock

Calliditas Therapeutics Stock

CALTX.ST
SE0010441584
A2JP36

Price

206.00
Today +/-
+0
Today %
+0 %
P

Calliditas Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Calliditas Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Calliditas Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Calliditas Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Calliditas Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Calliditas Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Calliditas Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Calliditas Therapeutics’s growth potential.

Calliditas Therapeutics Revenue, EBIT and net profit per share

DateCalliditas Therapeutics RevenueCalliditas Therapeutics EBITCalliditas Therapeutics Net Income
2029e4.7 B undefined0 undefined0 undefined
2028e6.35 B undefined3.27 B undefined7.53 B undefined
2027e6.13 B undefined3.33 B undefined5.5 B undefined
2026e4.87 B undefined2.6 B undefined1.81 B undefined
2025e3.44 B undefined1.35 B undefined920.91 M undefined
2024e2.12 B undefined354.66 M undefined157.55 M undefined
20231.21 B undefined-390.58 M undefined-466.19 M undefined
2022802.88 M undefined-414.81 M undefined-412.27 M undefined
2021229.35 M undefined-524.61 M undefined-500.29 M undefined
2020874,000 undefined-382.2 M undefined-433.49 M undefined
2019184.83 M undefined-27.88 M undefined-32.58 M undefined
20180 undefined-132.48 M undefined-132.05 M undefined
20170 undefined-84.51 M undefined-86.79 M undefined
20160 undefined-56.02 M undefined-56.91 M undefined
20150 undefined-50.91 M undefined-51.01 M undefined

Calliditas Therapeutics Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000.1800.230.81.212.123.444.876.136.354.7
-------250.2250.3775.6262.5641.3625.913.67-26.03
-------98.1395.02------
00000000.791.15000000
-0.05-0.06-0.08-0.13-0.03-0.38-0.52-0.41-0.390.351.352.63.333.270
-----14.67--228.82-51.62-32.3416.7139.1553.4854.3751.39-
-0.05-0.06-0.09-0.13-0.03-0.43-0.5-0.41-0.470.160.921.815.57.530
-9.8053.5753.49-75.761,253.1315.47-17.6013.11-133.69485.9996.85203.8136.77-
33.2333.2333.2325.9536.9444.8750.8353.0253.67000000
- - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Calliditas Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Calliditas Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Calliditas Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Calliditas Therapeutics's financial health and stability.

Assets

Calliditas Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Calliditas Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Calliditas Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Calliditas Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-50-56-84-132-28-379-524-421-373
00001,0000000
000000000
10164-4555-349-164
00000156661102
00000053594
0000003722
-48-55-68-128-71-309-461-311-434
0000-160-22-20
0000-18-172-24-5-13
0000-1-172-1-2-13
000000000
030360-1-3179480199
55243741213950324950
5554101716198768435575199
0061-24-12-178-6700
000000000
5033588107242-40293-275
-48.91-55.69-68.01-128.19-87.2-309.18-484.24-313.87-434.66
000000000

Calliditas Therapeutics stock margins

The Calliditas Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Calliditas Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Calliditas Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Calliditas Therapeutics's sales revenue. A higher gross margin percentage indicates that the Calliditas Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Calliditas Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Calliditas Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Calliditas Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Calliditas Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Calliditas Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Calliditas Therapeutics Margin History

Calliditas Therapeutics Gross marginCalliditas Therapeutics Profit marginCalliditas Therapeutics EBIT marginCalliditas Therapeutics Profit margin
2029e94.99 %0 %0 %
2028e94.99 %51.39 %118.46 %
2027e94.99 %54.37 %89.8 %
2026e94.99 %53.47 %37.22 %
2025e94.99 %39.15 %26.75 %
2024e94.99 %16.75 %7.44 %
202394.99 %-32.36 %-38.63 %
202298.11 %-51.67 %-51.35 %
202194.99 %-228.74 %-218.14 %
202094.99 %-43,730.21 %-49,598.85 %
201994.99 %-15.08 %-17.63 %
201894.99 %0 %0 %
201794.99 %0 %0 %
201694.99 %0 %0 %
201594.99 %0 %0 %

Calliditas Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Calliditas Therapeutics earnings per share therefore indicates how much revenue Calliditas Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Calliditas Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Calliditas Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Calliditas Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Calliditas Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Calliditas Therapeutics Revenue, EBIT and net profit per share

DateCalliditas Therapeutics Sales per ShareCalliditas Therapeutics EBIT per shareCalliditas Therapeutics Earnings per Share
2029e87.55 undefined0 undefined0 undefined
2028e118.37 undefined0 undefined140.21 undefined
2027e114.17 undefined0 undefined102.52 undefined
2026e90.7 undefined0 undefined33.76 undefined
2025e64.15 undefined0 undefined17.16 undefined
2024e39.46 undefined0 undefined2.94 undefined
202322.49 undefined-7.28 undefined-8.69 undefined
202215.14 undefined-7.82 undefined-7.78 undefined
20214.51 undefined-10.32 undefined-9.84 undefined
20200.02 undefined-8.52 undefined-9.66 undefined
20195 undefined-0.75 undefined-0.88 undefined
20180 undefined-5.11 undefined-5.09 undefined
20170 undefined-2.54 undefined-2.61 undefined
20160 undefined-1.69 undefined-1.71 undefined
20150 undefined-1.53 undefined-1.54 undefined

Calliditas Therapeutics business model

Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden. The company's goal is to develop innovative therapies for rare diseases and treat patients worldwide. The company is divided into two main business areas: clinical development and commercial products. The clinical development area focuses on identifying, developing, and marketing drugs for the treatment of kidney and liver diseases, as well as autoimmune diseases. The commercial products area distributes the developed medications. Calliditas' business model is based on the discovery and exploration of therapies for rare diseases. The company divides its pipeline into different product categories such as kidney and liver diseases, as well as autoimmune diseases. It is expected that this pipeline will make further progress over time and bring several products to market. Currently, Calliditas is in Phase 3 of clinical trials for Nefecon, a medication for the treatment of IgA nephropathy. IgA nephropathy is a rare kidney disease in which immunoglobulin A deposits in the kidneys can cause inflammation and damage. Nefecon is being developed to reduce the production of IgA and thereby reduce inflammation in the kidneys. Calliditas is also in Phase 2 of clinical trials for Atimmune, a medication for the treatment of autoimmune diseases. Atimmune aims to modulate the immune system to treat autoimmune diseases naturally. In addition, Calliditas is currently working on another medication for the treatment of liver diseases called FT-4202. FT-4202 is intended to increase the production of hemoglobin and thereby alleviate the symptoms of sickle cell anemia. Calliditas has an experienced team of researchers, clinicians, and salespeople dedicated to the development of medications for rare diseases. The company collaborates closely with experts in the field of kidney and liver diseases, as well as autoimmune diseases, to improve the development and marketing of its products. The company has also formed partnerships with other companies and industry stakeholders to support its research and development efforts. For example, Calliditas has entered into an agreement with Everest Medicines Ltd., a Chinese biotech company specializing in rare diseases, to market and distribute Nefecon in China. Overall, Calliditas has a promising pipeline of medications for the treatment of rare diseases. The company is well positioned to succeed in the coming years and improve the lives of patients around the world. Calliditas Therapeutics is one of the most popular companies on Eulerpool.com.

Calliditas Therapeutics SWOT Analysis

Strengths

1. Strong Research and Development capabilities

2. Range of innovative and promising drug candidates in pipeline

3. Well-established collaborations and partnerships with key industry players

Weaknesses

1. Limited market presence and brand recognition compared to major competitors

2. Dependence on the success of clinical trials for drug candidates

3. Relatively small size and resources compared to industry leaders

Opportunities

1. Increasing demand for effective treatments in target therapeutic areas

2. Potential for strategic collaborations and licensing agreements

3. Expanding global pharmaceutical market

Threats

1. Intense competition from established pharmaceutical companies

2. Regulatory challenges and evolving market regulations

3. Potential risks associated with intellectual property rights

Calliditas Therapeutics valuation based on historical P/E ratio, EBIT, and P/S ratio.

Calliditas Therapeutics shares outstanding

The number of shares was Calliditas Therapeutics in 2023 — This indicates how many shares 53.672 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Calliditas Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Calliditas Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Calliditas Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Calliditas Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Calliditas Therapeutics.

Calliditas Therapeutics Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-1.69 -4.59  (-171.73 %)2024 Q1
12/31/2023-1.78 -0.34  (80.89 %)2023 Q4
9/30/2023-0.29 -3.14  (-979.04 %)2023 Q3
6/30/2023-2.22 -1.71  (22.9 %)2023 Q2
3/31/2023-1.75 -3.49  (-99.31 %)2023 Q1
12/31/2022-1.76 -0.07  (96.03 %)2022 Q4
9/30/2022-3.11 -0.17  (94.53 %)2022 Q3
6/30/2022-4.36 -3.62  (16.91 %)2022 Q2
12/31/2021-3.83 -4.19  (-9.35 %)2021 Q4
1

Eulerpool ESG Scorecard© for the Calliditas Therapeutics stock

Eulerpool World ESG Rating (EESG©)

61/ 100

🌱 Environment

69

👫 Social

32

🏛️ Governance

81

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees59
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Calliditas Therapeutics Stock Shareholders

%
Name
Stocks
Change
Date
5.86 % Industrifonden3,145,440012/31/2023
4.32 % Polar Capital LLP2,320,694570,69412/31/2023
3.91 % Avanza Bank Holding AB2,096,247-135,94512/31/2023
3.67 % Unionen1,971,692171,69212/31/2023
3.30 % Handelsbanken Kapitalförvaltning AB1,773,542-352,30012/31/2023
3.27 % Fjärde AP-Fonden1,754,603-418,11212/31/2023
2.62 % Sofinnova Partners1,408,078012/31/2023
2.48 % E.Öhman J:or Fonder AB1,329,142414,54412/31/2023
11.66 % BVF Partners L.P.6,260,311012/31/2023
11.11 % Julander (Bengt)5,962,312012/31/2023
1
2
3
4
5
...
9

Calliditas Therapeutics Executives and Management Board

Ms. Renee Aguiar-Lucander61
Calliditas Therapeutics Chief Executive Officer
Compensation 13.05 M
Mr. Elmar Schnee64
Calliditas Therapeutics Independent Chairman of the Board
Compensation 1.62 M
Ms. Molly Henderson53
Calliditas Therapeutics Non-Executive Independent Director
Compensation 817,000
Ms. Diane Parks71
Calliditas Therapeutics Non-Executive Independent Director
Compensation 729,000
Mrs. Hilde Furberg65
Calliditas Therapeutics Non-Executive Independent Director
Compensation 652,000
1
2
3
4

Calliditas Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Everest Medicines - Stock
Everest Medicines
SupplierCustomer0,890,970,630,230,69-
Linc - Stock
Linc
SupplierCustomer0,890,890,860,59--
Kyowa Kirin - Stock
Kyowa Kirin
SupplierCustomer0,040,820,47-0,38-0,04
Genkyotex - Stock
Genkyotex
SupplierCustomer-0,590,61-0,25-0,27-0,01-
Svenska Handelsbanken A - Stock
Svenska Handelsbanken A
SupplierCustomer-0,73-0,86-0,170,08-0,25
1

Calliditas Therapeutics stock: Frequently Asked Questions

What values and corporate philosophy does Calliditas Therapeutics represent?

Calliditas Therapeutics AB represents a set of core values and a corporate philosophy that focus on innovation, commitment, and patient-centricity. The company is dedicated to developing and commercializing therapies for patients with rare diseases and other unmet medical needs. Calliditas Therapeutics AB believes in fostering a culture of excellence, collaboration, and integrity to deliver meaningful and transformative healthcare solutions. With a strong emphasis on research and development, the company aims to improve patients' quality of life and provide hope for those suffering from chronic diseases.

In which countries and regions is Calliditas Therapeutics primarily present?

Calliditas Therapeutics AB is primarily present in several countries and regions worldwide. The company has a strong presence in the United States, where it operates through its subsidiary, Calliditas Therapeutics Inc. Additionally, Calliditas Therapeutics AB is actively engaged in Europe, with significant operations and market presence in countries like Sweden, Germany, France, and the United Kingdom. The company strives to expand its reach and establish a global footprint by establishing partnerships and collaborations in different geographies. Calliditas Therapeutics AB focuses on developing innovative therapies and improving patient outcomes, benefiting individuals in various countries and regions through its dedicated efforts.

What significant milestones has the company Calliditas Therapeutics achieved?

Calliditas Therapeutics AB has achieved several significant milestones. The company successfully completed a Phase 3 clinical trial for Nefecon, an investigational treatment for IgA nephropathy. In addition, Calliditas Therapeutics AB received Breakthrough Therapy designation from the U.S. FDA for Nefecon, recognizing its potential to address an unmet medical need. The company also entered into collaboration agreements with key partners, including Everest Medicines and Deva Holding, to further develop and commercialize its products. Furthermore, Calliditas Therapeutics AB successfully listed on the Nasdaq Stockholm exchange, improving visibility in the market. These achievements demonstrate the company's commitment to advancing innovative therapies and expanding its global presence.

What is the history and background of the company Calliditas Therapeutics?

Calliditas Therapeutics AB, a renowned biopharmaceutical company, has a rich history and background. Founded in 2004 and headquartered in Stockholm, Sweden, Calliditas focuses on developing novel treatments for rare kidney diseases. The company combines scientific expertise and innovative research to improve patients' lives. Calliditas Therapeutics AB went public in 2017 and trades on the Nasdaq Stockholm under the ticker symbol CALTX. With a strong commitment to patient care and leveraging cutting-edge technologies, Calliditas Therapeutics AB continues to make significant strides in the field of kidney disease therapies.

Who are the main competitors of Calliditas Therapeutics in the market?

The main competitors of Calliditas Therapeutics AB in the market include pharmaceutical companies such as Mallinckrodt, Advicenne, and Retrophin.

In which industries is Calliditas Therapeutics primarily active?

Calliditas Therapeutics AB is primarily active in the pharmaceutical industry. With a focus on developing and commercializing innovative treatments, Calliditas Therapeutics AB specializes in rare and orphan diseases. As a specialized biopharmaceutical company, Calliditas Therapeutics AB is dedicated to improving the quality of life for patients suffering from severe diseases.

What is the business model of Calliditas Therapeutics?

The business model of Calliditas Therapeutics AB is focused on developing and commercializing novel treatments for rare kidney diseases. The company aims to address unmet medical needs by developing innovative therapies and providing improved outcomes for patients. Calliditas Therapeutics AB conducts extensive research and development to create effective and safe treatments, incorporating clinical trials to evaluate their efficacy. By partnering with healthcare professionals, institutions, and stakeholders, Calliditas Therapeutics AB seeks to maximize patient access to its products and contribute to the advancement of renal care.

What is the P/E ratio of Calliditas Therapeutics 2024?

The Calliditas Therapeutics P/E ratio is 70.18.

What is the P/S ratio of Calliditas Therapeutics 2024?

The Calliditas Therapeutics P/S ratio is 5.22.

What is the AlleAktien quality score of Calliditas Therapeutics?

The AlleAktien quality score for Calliditas Therapeutics is 3/10.

What is the revenue of Calliditas Therapeutics 2024?

The expected Calliditas Therapeutics revenue is 2.12 B SEK.

How high is the profit of Calliditas Therapeutics 2024?

The expected Calliditas Therapeutics profit is 157.55 M SEK.

What is the business model of Calliditas Therapeutics

Calliditas Therapeutics AB is a Swedish biotechnology company focused on the development of medications for the treatment of rare diseases. The company was founded in 2004 and is headquartered in Stockholm. Calliditas is developing new therapeutic approaches for patients suffering from autoimmune and kidney diseases. The business model of Calliditas is based on the discovery, development, and commercialization of innovative medications that meet high medical needs and can have a significant impact on patients' lives. Calliditas conducts intensive research and development projects aimed at developing innovative drugs and treatment approaches that enable fast and effective healing. The main products of Calliditas are Nefecon, a medication for the treatment of IgA nephropathy, an inflammatory kidney disease, and Baylis Medical, which provides medical technology for diagnosing and treating kidney diseases. Nefecon is an innovative medication based on a unique proprietary technology platform that is designed to slow down the progression of IgA nephropathy. IgA nephropathy is a rare autoimmune disease that attacks the kidneys and can lead to irreversible damage. Calliditas also operates an extensive development program for a range of autoimmune diseases such as PBC, AAV, and Primary Sclerosing Cholangitis (PSC). Calliditas' research work aims to develop innovative drugs that target fast and effective treatment of these conditions. The company relies on a clinical pipeline that offers a wide range of potential therapy options. Calliditas has demonstrated a strong commitment to collaborating with leading academic institutions and the pharmaceutical industry to promote innovative research and utilize new technology platforms for drug development. The company strives to identify and build strategic partnerships. In summary, Calliditas is a leading biotechnology company developing innovative medications for the treatment of autoimmune and kidney diseases. The company has a clinical pipeline that offers a wide range of potential therapy options and is dedicated to research and development of innovative treatment approaches. Calliditas has built strong business partnerships with leading institutions and the pharmaceutical industry. The company aims to lead the healthcare industry in terms of research and innovation and improve the lives of patients worldwide.

What is the Calliditas Therapeutics dividend?

Calliditas Therapeutics pays a dividend of 0 SEK distributed over payouts per year.

How often does Calliditas Therapeutics pay dividends?

The dividend cannot currently be calculated for Calliditas Therapeutics or the company does not pay out a dividend.

What is the Calliditas Therapeutics ISIN?

The ISIN of Calliditas Therapeutics is SE0010441584.

What is the Calliditas Therapeutics WKN?

The WKN of Calliditas Therapeutics is A2JP36.

What is the Calliditas Therapeutics ticker?

The ticker of Calliditas Therapeutics is CALTX.ST.

How much dividend does Calliditas Therapeutics pay?

Over the past 12 months, Calliditas Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Calliditas Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of Calliditas Therapeutics?

The current dividend yield of Calliditas Therapeutics is .

When does Calliditas Therapeutics pay dividends?

Calliditas Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Calliditas Therapeutics?

Calliditas Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Calliditas Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Calliditas Therapeutics located?

Calliditas Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Calliditas Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Calliditas Therapeutics from 7/5/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.

When did Calliditas Therapeutics pay the last dividend?

The last dividend was paid out on 7/5/2024.

What was the dividend of Calliditas Therapeutics in the year 2023?

In the year 2023, Calliditas Therapeutics distributed 0 SEK as dividends.

In which currency does Calliditas Therapeutics pay out the dividend?

The dividends of Calliditas Therapeutics are distributed in SEK.

Other fundamentals and analyses of Calliditas Therapeutics in the deep dive.

Our stock analysis for Calliditas Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calliditas Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.